CDKN2A and diffuse large B-cell lymphoma: In non-germinal center B-cell diffuse large B-cell lymphoma (GBC-DLBCL), characterized by high MYC protein expression and CDKN2A/B deletion, concomitant inhibition of ATR and the WEE1 kinase leads to DNA damage and G1 and intra S-phase cell cycle arrest, which pair with a strong cytotoxic response in in vivo DLBCL models [113].